In the present analysis, we evaluated the impact of MGMT promoter methylation as well as IDH1 mutation status on recurrence-free interval (the period from beginning of adjuvant therapy after surgical resection to the possible first date of recurrence) in patients with glioblastoma. The gene discussed is MGMT; the disease is glioblastoma.